Immunome Inc
IMNM8.680USD
-0.240-2.69%
Cierre 06/25, 16:00（ET）Cotizaciones retrasadas 15 min
754.78MCap. mercado
PérdidaP/E TTM
Más Datos de Immunome Inc Compañía
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Información de la empresa
Símbolo de cotizaciónIMNM
Nombre de la empresaImmunome Inc
Fecha de salida a bolsaOct 02, 2020
Fundada en2015
Director ejecutivoDr. Clay B. Siegall, Ph.D.
Número de empleados118
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 02
Dirección18702 N. Creek Parkway
CiudadBOTHELL
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal98011
Teléfono16103213700
Sitio Webhttps://immunome.com/
Símbolo de cotizaciónIMNM
Fecha de salida a bolsaOct 02, 2020
Fundada en2015
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Ms. Sandra G. Stoneman
Ms. Sandra G. Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Chief Legal Officer, General Counsel, Corporate Secretary
--
--
Dr. Phil Tsai
Dr. Phil Tsai
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Sandra M Swain, M.D.
Dr. Sandra M Swain, M.D.
Independent Director
Independent Director
--
--
Dr. Bob Lechleider, M.D.
Dr. Bob Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Desglose de ingresos
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
9.04M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
8.68%
Redmile Group, LLC
6.16%
BlackRock Institutional Trust Company, N.A.
5.87%
Enavate Sciences GP, LLC
5.48%
Point72 Asset Management, L.P.
5.01%
Other
68.79%
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
8.68%
Redmile Group, LLC
6.16%
BlackRock Institutional Trust Company, N.A.
5.87%
Enavate Sciences GP, LLC
5.48%
Point72 Asset Management, L.P.
5.01%
Other
68.79%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
33.48%
Investment Advisor/Hedge Fund
29.43%
Hedge Fund
14.85%
Corporation
8.26%
Research Firm
4.28%
Individual Investor
3.23%
Venture Capital
0.91%
Bank and Trust
0.29%
Pension Fund
0.14%
Other
5.14%
Participación institucional
Actualizado: lun., 3 de mar
Actualizado: lun., 3 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
295
69.73M
91.15%
+848.96K
2024Q4
278
64.18M
84.45%
+3.64M
2024Q3
252
62.39M
103.49%
+7.38M
2024Q2
228
58.25M
97.90%
+16.13M
2024Q1
182
46.83M
84.41%
+22.74M
2023Q4
113
32.29M
78.79%
+19.76M
2023Q3
82
6.26M
40.47%
+930.23K
2023Q2
81
5.83M
36.98%
+582.43K
2023Q1
95
4.18M
34.54%
-644.30K
2022Q4
98
4.36M
36.09%
-940.25K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
T. Rowe Price Investment Management, Inc.
5.50M
6.33%
-262.06K
-4.55%
Dec 31, 2024
Redmile Group, LLC
4.83M
5.55%
-61.53K
-1.26%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.74M
4.3%
+134.54K
+3.73%
Dec 31, 2024
Enavate Sciences GP, LLC
3.48M
4%
+3.48M
--
Dec 31, 2024
The Vanguard Group, Inc.
3.00M
3.45%
-128.13K
-4.10%
Dec 31, 2024
EcoR1 Capital, LLC
3.88M
4.46%
--
--
Dec 31, 2024
Fidelity Management & Research Company LLC
3.92M
4.51%
-305.48K
-7.23%
Dec 31, 2024
Opaleye Management Inc.
2.04M
2.35%
+802.50K
+64.85%
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
WisdomTree BioRevolution Fund
0.97%
iShares Genomics Immunology and Healthcare ETF
0.71%
ALPS Medical Breakthroughs ETF
0.63%
Virtus LifeSci Biotech Clinical Trials ETF
0.5%
Main Thematic Innovation ETF
0.5%
SPDR S&P Biotech ETF
0.2%
iShares Micro-Cap ETF
0.15%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Nuveen ESG Small-Cap ETF
0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
0.05%
Ver más
WisdomTree BioRevolution Fund
Proporción0.97%
iShares Genomics Immunology and Healthcare ETF
Proporción0.71%
ALPS Medical Breakthroughs ETF
Proporción0.63%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.5%
Main Thematic Innovation ETF
Proporción0.5%
SPDR S&P Biotech ETF
Proporción0.2%
iShares Micro-Cap ETF
Proporción0.15%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.13%
Nuveen ESG Small-Cap ETF
Proporción0.06%
iShares ESG Aware MSCI USA Small-Cap ETF
Proporción0.05%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
